Milli-Mark Anti-CD8 -FITC Antibody, clone DK25

Description

• General description: CD8 is a 68 kDa disulphide-linked, transmembrane glycoprotein. The CD8 molecule serves as a receptor for MHC class I molecules and can mediate a function as a coreceptor in TCR-ligand binding and T-cell activation. Its cytoplasmic part is associated with the p56Ick tyrosine kinase (Nakuchi, 1997). CD8 is expressed by the great majority of cortical thymocytes and approximately 30% of medullary thymocytes, and by class I major histocompatibility complex restricted, mature suppressor/cytotoxic T cells. In addition a proportion of gamma delta T cells and NK cells express CD8 (Nakuchi, 1997). Thus, CD8 is expressed by about 25-35% of peripheral T cells, and about 30% of NK cells express low levels of CD8 (Leong, 1999). The specificity of Anti-CD8, DK25, is equivalent to that of the CD8-clustered antibodies OKT8 and Leu-2a (Stein, 1984).
• Specificity: Antibody recognizes Human CD8 antigen.
• Application: Milli-Mark Anti-CD8 -FITC Antibody, clone DK25 detects level of CD8 & has been published & validated for use in FC.
• Quality: Evaluated by flow cytomatry using human lymphocytes.
• Target description: 68 kDa (Nakuchi, 1997)
• Physical form: Protein A purified
• Storage and Stability: Maintain refrigerated at 2-8 °C protected from light in undiluted aliquots for up to 6 months from date of receipt.
• Analysis Note: ControlHuman Lympnocytes.
• Other Notes: Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
• Legal Information: MILLI-MARK is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.